Stereotaxis: Recurring Revenue Inflection

Core Insights - Stereotaxis, Inc. (NYSE: STXS) is making significant advancements in robotic interventional cardiology while the market remains underweight on the stock [1] - The company is expected to see recurring revenue growth exceeding 25% over the next 18 months [1] Company Overview - Stereotaxis is focused on innovating within the robotic interventional cardiology space, which is gaining attention amidst the broader focus on generative AI [1] - The market perception of Stereotaxis is currently undervalued, presenting a potential investment opportunity [1] Financial Outlook - The anticipated growth in recurring revenue indicates a positive shift in the company's financial trajectory, suggesting strong future performance [1]